Aytu Biopharma Inc Net Income per Employee (AYTU), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Aytu Biopharma Inc  (NASDAQ: AYTU)
 

Aytu Biopharma Inc Net Income per Employee

AYTU's Quarterly Results, Trends, Rankings, Statistics
Aytu Biopharma Inc recorded a cumulative net loss of $-34 million during 12 month ending in the third quarter 2026.
The Healthcare sector has seen employees of 351 other companies achieving higher income per employee. While Aytu Biopharma Inc's total ranking has deteriorated compared to the previous quarter from 3661 to 3963.


What is Income per Employee Ratio?






AYTU Net Income per Employee (Mar 31 2026)
III. Quarter
(Dec 31 2025)
II. Quarter
(Sep 30 2025)
I. Quarter
(Jun 30 2025)
IV. Quarter
(Mar 31 2025)
III. Quarter
Y / Y Net Income Change - - 33.31 % - -
Net Income per Employee (TTM) $ -2,128,438 -1,527,688 -816,938 -847,625 102,438
AYTU's Total Ranking # 3963 # 3661 # 3153 # 3206 # 808
Seq. Net Income Change - - - - 406.85 %


AYTU Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 352
Healthcare Sector # 785
Overall Market # 3963

Net Income per Employee Statistics
High Average Low
$ 102,438 $ -1,903,642 $ -6,966,874
(Mar 31 2025)   (Mar 31 2022)







Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2026Number of Employees Mar 31 2026


Date modified: 2026-08-29T17:22:18+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.